Natalizumab Withdrawn Phase 4 Trials for Crohn's Disease (CD) Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT00801125Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy